Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A real world study of Ranibizumab in patients with visual impairment from the french BOREAL cohort.

Trial Profile

A real world study of Ranibizumab in patients with visual impairment from the french BOREAL cohort.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Retinal oedema
  • Focus Therapeutic Use
  • Acronyms BOREAL-DME
  • Most Recent Events

    • 26 Aug 2018 Final results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
    • 18 Sep 2017 New trial record
    • 30 Aug 2017 Results (n=290) assessing BCVA in patients with visual impairment due to diabetic macular edema presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top